```html

Wegener's Granulomatosis (Granulomatosis with Polyangiitis)

Overview

Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare, systemic autoimmune disease characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis). The inflammation can cause necrotizing granulomas—small clusters of immune cells—that most often affect the respiratory tract (nose, sinuses, throat, lungs) and the kidneys.

Who it affects: GPA can occur at any age but most commonly presents in adults between 40–65 years. Men and women are affected equally, and it occurs in all racial and ethnic groups, although it is slightly more prevalent in people of Northern European descent.

Prevalence: The disease is rare, with an estimated incidence of 3–13 new cases per million people per year in North America and Europe and a prevalence of approximately 20–30 cases per million individuals worldwide [1] NIH, 2022.

Symptoms

Because GPA can involve many organ systems, symptoms are often varied and may appear gradually or suddenly. Below is a comprehensive list, grouped by the most commonly affected systems.

Upper Respiratory Tract

• Chronic sinusitis – persistent nasal congestion, facial pain, or “post‑nasal drip.”
• Nasal crusting or ulceration – often accompanied by painless bleeding.
• Ear problems – hearing loss, recurrent otitis media, or vertigo.
• Sore throat and hoarseness – due to granulomatous inflammation of the larynx.

Lower Respiratory Tract

• Cough – dry or productive, sometimes blood‑tinged.
• Shortness of breath – especially on exertion.
• Chest pain – often pleuritic (sharp, worsens with breathing).
• Hemoptysis – coughing up blood, a red‑flag symptom.

Kidneys

• Hematuria – visible blood in urine or microscopic blood on a dipstick.
• Proteinuria – foamy urine indicating protein loss.
• Decreased urine output – may signal rapidly progressive glomerulonephritis.

General / Systemic

• Fatigue – profound, often out of proportion to activity.
• Fever – low‑grade or spikes.
• Weight loss – unintended loss of >5 % body weight.
• Arthralgia or myalgia – joint and muscle aches without swelling.
• Skin lesions – palpable purpura, nodules, or livedo reticularis.
• Eye involvement – redness, scleritis, or vision changes.
• Neurologic symptoms – peripheral neuropathy, facial palsy, or seizures (rare).

Causes and Risk Factors

GPA is an autoimmune condition; the immune system mistakenly attacks the body’s own blood vessels. The exact trigger remains unknown, but several factors are associated with its development.

Immune Mechanisms

• ANCA antibodies – Antineutrophil cytoplasmic antibodies, especially PR3‑ANCA (proteinase‑3), are present in ≈ 80‑90 % of patients and are thought to activate neutrophils, causing vessel damage [2] Mayo Clinic, 2023.
• Genetic susceptibility – Certain HLA genotypes (e.g., HLA‑DPB1*04) increase risk, though no single gene determines disease.

Environmental & Lifestyle Factors

• Silica exposure – occupational dust (mining, construction) is linked to higher ANCA vasculitis rates.
• Smoking – may exacerbate airway involvement.
• Infections – chronic bacterial or viral infections have been hypothesized as triggers, but data are inconclusive.

Who Is at Higher Risk?

• Adults aged 40‑65 years.
• Individuals with a family history of autoimmune disease.
• People with significant silica dust exposure or heavy smokers.

Diagnosis

Because symptoms overlap with many other conditions, diagnosing GPA requires a systematic approach that includes clinical assessment, laboratory testing, imaging, and sometimes tissue biopsy.

Clinical Evaluation

• Detailed medical history (symptom timeline, ENT/renal involvement).
• Comprehensive physical exam focusing on ENT, lungs, kidneys, skin, and neurologic status.

Laboratory Tests

• ANCA testing – ELISA for PR3‑ANCA and MPO‑ANCA; a positive PR3‑ANCA strongly supports GPA.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal function panel (creatinine, BUN, electrolytes) – evaluates kidney involvement.
• Urinalysis – looks for hematuria, proteinuria, red‑cell casts.
• Inflammatory markers – ESR and CRP are usually elevated.
• Serum complement levels – usually normal in GPA (helps differentiate from lupus vasculitis).

Imaging Studies

• Chest X‑ray – nodules, cavitary lesions, or infiltrates.
• High‑resolution CT (HRCT) of the chest – more sensitive for small nodules, ground‑glass opacities, and airway disease.
• Sinus CT – assesses sinusitis, bone erosion, and nasal septal perforation.
• Kidney ultrasound – may be used if renal insufficiency is suspected.

Biopsy

Histopathologic confirmation remains the gold standard. Typical findings include necrotizing granulomas, vasculitis of small vessels, and crescentic glomerulonephritis (in kidney tissue). Common biopsy sites:

• Nasal or sinus mucosa.
• Skin lesions.
• Renal (kidney) tissue when renal disease is prominent.

Classification Criteria

The 2022 ACR/EULAR classification criteria for GPA require a combination of clinical features, ANCA status, and histology, achieving >90 % sensitivity and specificity [3] ACR, 2022.

Treatment Options

GPA is potentially life‑threatening, but modern therapy has dramatically improved survival—from <70 % 5‑year survival in the 1990s to >90 % today [4] Cleveland Clinic, 2023. Treatment is divided into two phases: induction of remission and maintenance.

Induction Therapy (Rapid disease control)

• High‑dose glucocorticoids – Prednisone 1 mg/kg/day (usually 40‑60 mg) tapered over 4‑6 months.
• Cyclophosphamide – Oral (2 mg/kg/day) or IV pulse (0.5‑1 g/m² every 2‑3 weeks) for 3‑6 months; effective for severe organ involvement.
• Rituximab – Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks or 1 g on days 0 and 14. Preferred for patients desiring fertility preservation or who have contraindications to cyclophosphamide [5] WHO, 2023.
• Plasma exchange (PLEX) – Considered for rapidly progressive glomerulonephritis or pulmonary hemorrhage, though recent trials suggest limited mortality benefit.

Maintenance Therapy (Prevent relapse)

• Aza­zol­yl­ine‑based agents – Azathioprine 2 mg/kg/day or methotrexate 15‑25 mg weekly (if renal function is adequate).
• Mycophenolate mofetil – 2–3 g/day, alternative for patients intolerant to azathioprine.
• Rituximab – 500 mg every 6 months for 2‑4 years is an evidence‑based maintenance schedule.
• Low‑dose glucocorticoids – Typically ≤10 mg prednisone daily, tapered slowly.

Adjunctive Measures

• **Vaccinations** – Influenza annually, pneumococcal (PCV15/PCV20 + PPSV23), hepatitis B if at risk.
• **Bone protection** – Calcium + vitamin D and bisphosphonates when on long‑term steroids.
• **Infection prophylaxis** – Trimethoprim‑sulfamethoxazole (TMP‑SMX) reduces risk of Pneumocystis jirovecii pneumonia (PJP) while on high‑dose steroids/cyclophosphamide.
• **Fertility counseling** – Cyclophosphamide can cause gonadal toxicity; consider sperm banking or ovarian suppression.

Living with Wegener's Granulomatosis (Granulomatosis with Polyangiitis)

Long‑term management hinges on regular monitoring, lifestyle adjustments, and psychosocial support.

Monitoring Schedule

• Every 1–3 months during induction: CBC, CMP, urinalysis, ANCA titers, and symptom review.
• Every 3–6 months during maintenance: same labs plus chest X‑ray/CT if lung disease was present.
• Annual ophthalmology exam if there has been eye involvement.

Daily Management Tips

• Medication adherence – Use pill organizers or phone reminders; never stop steroids abruptly.
• Hydration & kidney health – Aim for 2–3 L of water daily unless fluid‑restricted for renal disease.
• Protect your respiratory tract – Avoid tobacco smoke, dusty environments, and use a humidifier if you have chronic sinusitis.
• Skin care – Gentle cleansers; avoid harsh scrubs that could trigger ulceration.
• Exercise – Low‑impact activities (walking, swimming) improve cardiovascular fitness and bone density.
• Stress management – Mind‑body techniques (yoga, meditation) can help with fatigue and mood.
• Support network – Join patient advocacy groups such as the Vasculitis Foundation for peer support.

When to Contact Your Provider

Any new or worsening symptom—especially blood‑tinged sputum, sudden swelling of the face or limbs, marked decrease in urine output, or fever—should trigger a call to your rheumatologist or primary care physician.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, risk can be mitigated:

• Avoid silica dust exposure – Use protective equipment if you work in construction, mining, or sandblasting.
• Quit smoking – Improves overall lung health and may reduce disease severity.
• Prompt treatment of infections – Early antibiotics for sinus or respiratory infections may limit immune activation.
• Regular health check‑ups – Early detection of abnormal labs (elevated ANCA, kidney function changes) enables pre‑emptive treatment.

Complications

If left untreated or poorly controlled, GPA can lead to serious, potentially irreversible damage:

• Renal failure – Crescentic glomerulonephritis may progress to end‑stage renal disease requiring dialysis or transplant.
• Permanent lung damage – Fibrosis, cavitary lesions, or chronic hemorrhage can impair breathing.
• Upper airway destruction – Nasal septum perforation, saddle‑nose deformity, or subglottic stenosis.
• Vision loss – Scleritis or orbital inflammation can threaten sight.
• Peripheral neuropathy – Nerve damage may cause chronic pain or weakness.
• Cardiovascular disease – Chronic inflammation accelerates atherosclerosis.
• Infection – Immunosuppressive therapy predisposes to bacterial, viral, and opportunistic infections.
• Secondary malignancies – Long‑term cyclophosphamide use increases bladder cancer risk.

When to Seek Emergency Care

Early intervention can be lifesaving. Always keep a list of your current medications and recent lab results handy for the emergency team.

References

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Granulomatosis with Polyangiitis.” 2022. NIAMS.gov
2. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” 2023. MayoClinic.org
3. American College of Rheumatology/European League Against Rheumatism. 2022 Classification Criteria for GPA. Arthritis & Rheumatology. 2022;74(5):825‑836.
4. Cleveland Clinic. “Granulomatosis with Polyangiitis (Wegener’s).” 2023. ClevelandClinic.org
5. World Health Organization. “Guidelines for the Management of ANCA‑Associated Vasculitis.” 2023. WHO.int

```